ASH 2023 | The evolving role of alloSCT in treatment of lymphoma
Issa Khouri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how the role of allogeneic stem cell transplantation (alloSCT) for treating lymphoma has changed with the advent of immunological therapies and provides his opinion on why alloSCT remains crucial in the treatment of patients. Only a relatively small proportion of patients respond to CAR T-cell therapy, and following the treatment, cells no longer express CD19. This means that CD20 must be targeted, and Dr Khouri believes that alloSCT, in combination with inotuzumab ozogamicin, will remain vital in treating these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Pfizer
